DSGN News and Press, Design Therapeutics Inc.

2026-03-09 16:03:26 ET More on Design Therapeutics Seeking Alpha’s Quant Rating on Design Therapeutics Historical earnings data for Design Therapeutics Financial information for Design Therapeutics Read the full article on Seeking Alpha For fur...

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution CARLSBAD, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics,...

New Fortress Energy Inc. (NFE) is expected to report $-1.08 for Q4 2025 Design Therapeutics Inc. (DSGN) is expected to report $-0.38 for Q4 2025 Beta Technologies Inc. Class A (BETA) is expected to report $-0.52 for Q4 2025 Yext Inc. (YEXT) is expected to report $0.06 for Q4 2026 ...

2025-12-03 08:06:41 ET Adam Vogel from Craig-Hallum issued a price target of $15.00 for DSGN on 2025-12-03 12:38:46. The adjusted price target was set to $15.00. At the time of the announcement, DSGN was trading at $8.94. The overall price target consensus is at $14.00 w...

CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in fireside chats at the following upcoming invest...

2025-11-20 11:57:19 ET More on Design Therapeutics Design Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 Transcript Design Therapeutics GAAP EPS of -$0.30 beats by $0.04 Seeking Alpha’s Quant Rating on Design Therapeutics ...

2025-11-06 16:59:15 ET Shares of gene therapy concern Lexeo Therapeutics, Inc. ( LXEO ) have roughly tripled since a financing in May 2025, partly on the back of FDA alignment on a registrational trial for its LX2006 therapy. Announced on October 7th, its pivotal study...

2025-11-06 09:19:30 ET More on Design Therapeutics Design Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 Transcript Seeking Alpha’s Quant Rating on Design Therapeutics Historical earnings data for Design Therapeutics Fin...

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial Corneal Dystrophy (FECD) Ongoing Cash and Securities of $206.0 M...